Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors

Figure 1 Comparison of alpha-fetoprotein, glypican-3 and alpha-fetoprotein-L3 levels before and after treatment between the two groups. A: Alpha-fetoprotein (AFP); B: Glypican-3; C: AFP-L3 levels before and after treatment between the two groups. ^aP < 0.05 compared with the same group before treatment; ^bP < 0.05 compared with the control group after treatment. AFP: Alpha-fetoprotein; GPC-3: Glypican-3.

Figure 2 The 1-, 2-, and 3-year follow-up survival curves of the two groups. A: 1-year follow-up survival curves; B: 2-year follow-up survival curves for the two groups; C: 3-year follow-up survival curves for the two groups.